TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis
Brief Summary: To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)


Options:
A: Arm Label: FTY720 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: FTY720 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720 0.5 mg, FTY720 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Threshold estimates; Type: EXPERIMENTAL; Interventions: Other: descriptive case-scenarios | Arm Label: Alternative threshold estimates; Type: ACTIVE_COMPARATOR; Interventions: Other: descriptive case-scenarios | Intervention Type: OTHER; Name: descriptive case-scenarios; Assigned to Arm(s): Alternative threshold estimates, Threshold estimates
C: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
D: Arm Label: Natalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Natalizumab | Arm Label: Interferon-beta-1b; Type: EXPERIMENTAL; Interventions: Drug: interferon beta-1b | Intervention Type: DRUG; Name: interferon beta-1b; Assigned to Arm(s): Interferon-beta-1b | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Natalizumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis
Brief Summary: To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)


Options:
A: Arm Label: FTY720 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: FTY720 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720 0.5 mg, FTY720 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod 0.5 mg, Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fingolimod; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Multiple Sclerosis Disease Modifying Treatments (MS DMTs); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard MS DMTs | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod | Intervention Type: DRUG; Name: Standard MS DMTs; Assigned to Arm(s): Multiple Sclerosis Disease Modifying Treatments (MS DMTs)
D: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis
Brief Summary: To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)


Options:
A: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate
B: Arm Label: FTY720 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: FTY720 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720 0.5 mg, FTY720 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis
Brief Summary: To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)


Options:
A: Arm Label: FTY720 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: FTY720 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720 0.5 mg, FTY720 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): Placebo
C: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate
D: Arm Label: BG00012 plus placebo; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate, Drug: Placebo | Arm Label: BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Intervention Type: DRUG; Name: dimethyl fumarate; Assigned to Arm(s): BG00012, BG00012 plus placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 plus placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures
Brief Summary: This study will compare pregabalin and levetiracetam in patients with partial seizures. It will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.


Options:
A: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: levetiracetam | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: levetiracetam; Assigned to Arm(s): A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pregabalin add-on therapy | Arm Label: Pregabalin Level 1 (max 150 mg/day); Type: EXPERIMENTAL; Interventions: Drug: Pregabalin add-on therapy | Arm Label: Pregabalin Level 2 (max 600 mg day); Type: EXPERIMENTAL; Interventions: Drug: Pregabalin add-on therapy | Intervention Type: DRUG; Name: Pregabalin add-on therapy; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pregabalin add-on therapy; Assigned to Arm(s): Pregabalin Level 1 (max 150 mg/day) | Intervention Type: DRUG; Name: Pregabalin add-on therapy; Assigned to Arm(s): Pregabalin Level 2 (max 600 mg day)
C: Arm Label: Study Drug Level 1; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin Dose Level 1 | Arm Label: Study Drug Level 2; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin Dose Level 2 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin Dose Level 1; Assigned to Arm(s): Study Drug Level 1 | Intervention Type: DRUG; Name: Pregabalin Dose Level 2; Assigned to Arm(s): Study Drug Level 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: pregabalin CR 330 mg; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: pregabalin CR 165 mg; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 330 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 165 mg | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin CR 165 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients
Brief Summary: This study is meant to assess the effectiveness of idebenone on neurological outcome measures in patients with Friedreich's Ataxia over a 6 months period.


Options:
A: Intervention Type: PROCEDURE; Name: electronic diary; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: voice acoustics; Assigned to Arm(s): N/A
B: Arm Label: Arm 1 - 900 mg/day Idebenone; Type: EXPERIMENTAL; Interventions: Drug: Idebenone | Arm Label: Arm 2 - up to 2250 mg/day Idebenone; Type: EXPERIMENTAL; Interventions: Drug: Idebenone | Arm Label: Arm 3 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): Arm 1 - 900 mg/day Idebenone | Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): Arm 2 - up to 2250 mg/day Idebenone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3 - Placebo
C: Arm Label: Low Dose; Type: EXPERIMENTAL; Interventions: Drug: alpha-tocopherolquinone (A0001) | Arm Label: High Dose; Type: EXPERIMENTAL; Interventions: Drug: alpha-tocopherolquinone (A0001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: alpha-tocopherolquinone (A0001); Assigned to Arm(s): Low Dose | Intervention Type: DRUG; Name: alpha-tocopherolquinone (A0001); Assigned to Arm(s): High Dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Mesh Fixation Technique on Postoperative Pain in Laparoscopic Correction of Incisional and Ventral Abdominal Wall Hernias.
Brief Summary: Method of fixation of the mesh in laparoscopic incisional / ventral hernia repair might influence the degree of postoperative pain.

The study hypothesis is that there is no difference in postoperative pain between different methods to fix the mesh in laparoscopic incisional / ventral hernia repair.


Options:
A: Arm Label: 0; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic correction of hernia with mesh | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic correction of hernia with mesh | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic correction of hernia with mesh | Intervention Type: PROCEDURE; Name: laparoscopic correction of hernia with mesh; Assigned to Arm(s): 0, 1, 2
B: Arm Label: 1: tacks; Type: ACTIVE_COMPARATOR; Interventions: Procedure: tack fixation of mesh | Arm Label: 2: glue; Type: EXPERIMENTAL; Interventions: Procedure: glue fixation of mesh | Intervention Type: PROCEDURE; Name: tack fixation of mesh; Assigned to Arm(s): 1: tacks | Intervention Type: PROCEDURE; Name: glue fixation of mesh; Assigned to Arm(s): 2: glue
C: Intervention Type: PROCEDURE; Name: Retromuscular Mesh repair of midline incisional hernia; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Laparoscopic repair of midline incisional hernia; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: OTHER; Interventions: Procedure: Open mesh repair of ventral incisional hernia, Procedure: Laparoscopic mesh repair of ventral incisional hernia | Intervention Type: PROCEDURE; Name: Open mesh repair of ventral incisional hernia; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Laparoscopic mesh repair of ventral incisional hernia; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.
Brief Summary: To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 2.5 mg | Arm Label: BRV 20mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 10 mg | Arm Label: BRV 50mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 25 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam 2.5 mg; Assigned to Arm(s): Brivaracetam 5 mg/day | Intervention Type: DRUG; Name: Brivaracetam 10 mg; Assigned to Arm(s): BRV 20mg/day | Intervention Type: DRUG; Name: Brivaracetam 25 mg; Assigned to Arm(s): BRV 50mg/day
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 100 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 200 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/ day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 200 mg/ day | Intervention Type: DRUG; Name: Antiepileptic drugs with market authorization available per country; Assigned to Arm(s): Brivaracetam 100 mg/ day, Brivaracetam 200 mg/ day, Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 100 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/day
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gabapentin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Pilot Trial of Oral Cyclophosphamide Versus Oral Cyclophosphamide With Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with celecoxib may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying how well giving cyclophosphamide together with celecoxib works compared to cyclophosphamide alone in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cancer.


Options:
A: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide, Drug: celecoxib | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): Arm II
B: Arm Label: Control Arm; Type: OTHER; Interventions: Biological: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin, Other: specialized pathology review (Germany only) | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Other: specialized pathology review (Germany only) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Control Arm | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Control Arm, Research Arm | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Control Arm, Research Arm | Intervention Type: OTHER; Name: specialized pathology review (Germany only); Assigned to Arm(s): Control Arm, Research Arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
D: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder
Brief Summary: The aim of the study was to investigate if the addition of cognitive behavioural therapy to treatment as usual (CBT plus TAU) in participants with borderline personality disorder would decrease the number of participants with emergency (i.e. unplanned) psychiatric or accident and emergency room contact or episode of deliberate self-harm over twelve months treatment and twelve months follow-up, compared with treatment as usual (TAU). The study also examined whether CBT plus TAU would lead to superior improvement in quality of life, social, cognitive and mental health functioning than TAU alone.


Options:
A: Arm Label: Relaxation group; Type: ACTIVE_COMPARATOR; Interventions: Other: Relaxation group | Arm Label: Psychoeducational group; Type: EXPERIMENTAL; Interventions: Behavioral: Interventional group : PEPSUI psychoeducational program | Intervention Type: BEHAVIORAL; Name: Interventional group : PEPSUI psychoeducational program; Assigned to Arm(s): Psychoeducational group | Intervention Type: OTHER; Name: Relaxation group; Assigned to Arm(s): Relaxation group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy, Other: Treatment as usual | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): 1, 2
C: Arm Label: Zero Suicide Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Zero Suicide Usual Care | Arm Label: Zero Suicide Usual Care + ASSIP; Type: EXPERIMENTAL; Interventions: Behavioral: Attempted Suicide Short Intervention Program | Intervention Type: BEHAVIORAL; Name: Attempted Suicide Short Intervention Program; Assigned to Arm(s): Zero Suicide Usual Care + ASSIP | Intervention Type: BEHAVIORAL; Name: Zero Suicide Usual Care; Assigned to Arm(s): Zero Suicide Usual Care
D: Arm Label: Post Admission Cognitive Therapy (PACT); Type: EXPERIMENTAL; Interventions: Behavioral: Post Admission Cognitive Therapy (PACT) | Arm Label: Enhanced Usual Care (EUC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Post Admission Cognitive Therapy (PACT); Assigned to Arm(s): Post Admission Cognitive Therapy (PACT)

Answer: B